Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Harpoon Therapeutics, Inc. (Nasdaq: HARP) announces that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Harpoon for $23.00 per share in cash for an approximate total equity value of $680 million. Harpoon has developed a portfolio of novel T-cell engagers that employ the company’s proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, an engineered protein technology designed to direct a patient’s own immune cells to kill tumor cells, and ProTriTAC™ platform, applying a prodrug concept to its TriTAC® platform to create a therapeutic T-cell engager that is designed to remain inactive until it reaches the tumor.

Read the full article: Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline //

Source: https://www.businesswire.com/news/home/20240108498651/en/Merck-to-Acquire-Harpoon-Therapeutics-Further-Diversifying-Oncology-Pipeline

Leave a Comment

Your email address will not be published.

Scroll to Top